UroGen Pharma
URGN
60 hedge funds and large institutions have $111M invested in UroGen Pharma in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 9 increasing their positions, 23 reducing their positions, and 10 closing their positions.
40,600% more call options, than puts
Call options by funds: $407K | Put options by funds: $1K
1% more capital invested
Capital invested by funds: $109M → $111M (+$1.57M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.68% less ownership
Funds ownership: 59.26% → 58.58% (-0.68%)
8% less funds holding
Funds holding: 65 → 60 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
61% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.31M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$679K |
| 3 |
JP Morgan Chase
New York
|
+$319K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$147K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.46M |
| 2 |
Morgan Stanley
New York
|
-$317K |
| 3 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
-$298K |
| 4 |
State Street
Boston,
Massachusetts
|
-$273K |
| 5 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
-$252K |
URGN Hedge Fund Activity: Q3 2022 in Review
60 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2022, worth a combined $111M — up 1.4% from $109M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of URGN and 5 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 9 added.
The largest buyer was Opaleye Management, adding an estimated $1.31M. The largest seller was Millennium Management, cutting an estimated $1.46M.
- 60 institutional investors held UroGen Pharma (URGN) as of Q3 2022, down from 65 in Q2 2022.
- Funds reported $111M of UroGen Pharma stock for Q3 2022, up 1.4% quarter-over-quarter.
- 5 funds opened new UroGen Pharma positions in Q3 2022 and 10 closed out, a net change of -5 holders.
- The largest UroGen Pharma buyer in Q3 2022 was Opaleye Management, an estimated $1.31M added.
- The largest UroGen Pharma seller in Q3 2022 was Millennium Management, an estimated $1.46M sold.
Based on aggregated 13F filings for Q3 2022.